WO2009087682A3 - Nouvelle formulation de prégabaline injectable stabilisée - Google Patents

Nouvelle formulation de prégabaline injectable stabilisée Download PDF

Info

Publication number
WO2009087682A3
WO2009087682A3 PCT/IN2008/000869 IN2008000869W WO2009087682A3 WO 2009087682 A3 WO2009087682 A3 WO 2009087682A3 IN 2008000869 W IN2008000869 W IN 2008000869W WO 2009087682 A3 WO2009087682 A3 WO 2009087682A3
Authority
WO
WIPO (PCT)
Prior art keywords
pregabalin
injectable formulation
formulation
injectable
stabilized injectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2008/000869
Other languages
English (en)
Other versions
WO2009087682A2 (fr
Inventor
Sehgal Ashish
Vallabhabhai Patel Bhavesh
Patel Aditya
Kumar Mandal Jayanta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intas Pharmaceuticals Ltd
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Priority to EP08869815A priority Critical patent/EP2240158A2/fr
Publication of WO2009087682A2 publication Critical patent/WO2009087682A2/fr
Publication of WO2009087682A3 publication Critical patent/WO2009087682A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur une formulation injectable de prégabaline stable, de pH située entre 4,0 et 8,0. En outre, la présente invention porte sur un procédé de fabrication de la formulation de prégabaline injectable. La formulation de prégabaline injectable proposée par la présente invention est administrée par voie intraveineuse à des patients nécessitant un traitement à la prégabaline.
PCT/IN2008/000869 2007-12-28 2008-12-26 Nouvelle formulation de prégabaline injectable stabilisée Ceased WO2009087682A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08869815A EP2240158A2 (fr) 2007-12-28 2008-12-26 Formulation de prégabaline injectable stabilisée

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2596/MUM/2007 2007-12-28
IN2596MU2007 2007-12-28

Publications (2)

Publication Number Publication Date
WO2009087682A2 WO2009087682A2 (fr) 2009-07-16
WO2009087682A3 true WO2009087682A3 (fr) 2009-09-11

Family

ID=40801860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000869 Ceased WO2009087682A2 (fr) 2007-12-28 2008-12-26 Nouvelle formulation de prégabaline injectable stabilisée

Country Status (2)

Country Link
EP (1) EP2240158A2 (fr)
WO (1) WO2009087682A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498611B (zh) * 2019-01-15 2020-09-01 张惊宇 一种治疗糖尿病周围神经痛的药物及其用途
FI3946260T3 (fi) * 2019-03-26 2026-03-24 Orion Corp Pregabaliiniformulaatioita ja niiden käyttö
EP4138818B1 (fr) * 2020-08-28 2024-08-21 Cybin UK Ltd Formulation injectable
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CN113069411B (zh) * 2021-04-02 2022-08-09 石家庄四药有限公司 一种己酮可可碱注射液及其制备方法
WO2022256545A1 (fr) * 2021-06-04 2022-12-08 Nevakar Injectables Inc. Formulations de prégabaline injectables
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
GB2624861A (en) 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof
GB2639602A (en) 2024-03-19 2025-10-01 Novumgen Ltd An orodispersible tablet of pregabalin and its process of preparation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058641A1 (fr) * 1997-06-25 1998-12-30 Warner-Lambert Company Utilisation d'analogues de gaba, telle la gabapentine, dans la fabrication d'un medicament servant a traiter des maladies inflammatoires
WO2000061135A1 (fr) * 1999-04-08 2000-10-19 Warner-Lambert Company Methode de traitement pour l'incontinence
WO2003061656A1 (fr) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
US20050090550A1 (en) * 2003-09-11 2005-04-28 Barrett Ronald W. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
US20060229361A1 (en) * 2005-04-06 2006-10-12 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20060281816A1 (en) * 2005-04-11 2006-12-14 Lilach Hedvati Pregabalin free of lactam and a process for preparation thereof
EP1992609A1 (fr) * 2007-05-14 2008-11-19 Dipharma Francis S.r.l. Processus de préparation d'acide (S)(+)-3-(aminomethyl)-5-methylhexanoique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058641A1 (fr) * 1997-06-25 1998-12-30 Warner-Lambert Company Utilisation d'analogues de gaba, telle la gabapentine, dans la fabrication d'un medicament servant a traiter des maladies inflammatoires
WO2000061135A1 (fr) * 1999-04-08 2000-10-19 Warner-Lambert Company Methode de traitement pour l'incontinence
WO2003061656A1 (fr) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
US20050090550A1 (en) * 2003-09-11 2005-04-28 Barrett Ronald W. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
US20060229361A1 (en) * 2005-04-06 2006-10-12 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20060281816A1 (en) * 2005-04-11 2006-12-14 Lilach Hedvati Pregabalin free of lactam and a process for preparation thereof
EP1992609A1 (fr) * 2007-05-14 2008-11-19 Dipharma Francis S.r.l. Processus de préparation d'acide (S)(+)-3-(aminomethyl)-5-methylhexanoique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI W ET AL: "DESIGN, SYNTHESIS, AND PRELIMINARY EVALUATION OF GABAPENTIN-PREGABALIN MUTUAL PRODRUGS IN RELIEVING NEUROPATHIC PAIN", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 338, no. 8, 1 January 2005 (2005-01-01), pages 358 - 364, XP008067446, ISSN: 0365-6233 *

Also Published As

Publication number Publication date
WO2009087682A2 (fr) 2009-07-16
EP2240158A2 (fr) 2010-10-20

Similar Documents

Publication Publication Date Title
MX2009012163A (es) Hetarilanilinas como moduladores para beta-amiloide.
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
NZ596187A (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2007115620A3 (fr) Nouveaux composés de cyclobutyle en tant qu'inhibiteurs de kinase
WO2006078463A3 (fr) Methode de traitement de maladie cardio-vasculaire
WO2007133731A3 (fr) Composés de ligand de créatine et procédés d'utilisation correspondants
WO2007133673A3 (fr) Procédés de traitement d'un trouble neurologique avec du monohydrate de créatine
WO2011023367A3 (fr) Promédicaments bisphosphonates
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2006058648A3 (fr) Acides biaryloxymethylarenecarboxyliques
WO2007010281A3 (fr) Utilisation de derives et d'analogues de thiazole dans les troubles causes par les acides gras libres
WO2007104485A3 (fr) Composés imidazo[2,1-b]thiazole substitués et utilisation dans la fabrication de médicaments
WO2007095021A3 (fr) Nouveaux composés
WO2008118792A3 (fr) Lymphocytes t gamma delta et procédés de traitement de problèmes liés à l'interleukine-17
WO2010021750A3 (fr) Procédés et compositions pour l'administration de 3-halopyruvate et de composés associés pour le traitement du cancer
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone
WO2010004031A3 (fr) Traitement inédit
WO2010039920A3 (fr) Composés à base de boldine pour favoriser la croissance osseuse
WO2008059041A3 (fr) Complémentation d'un déficit de facteur xi par mutants de facteur v
WO2008023003A8 (fr) Associations médicamenteuses destinées au traitement de maladies des voies respiratoires
WO2007056236A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse
WO2007092436A3 (fr) Composes pour le traitement de troubles inflammatoires, de troubles de demyelinisation et de cancers
WO2007116297A3 (fr) Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08869815

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008869815

Country of ref document: EP